Study guide

8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes

Key Takeaways Explain This Topic AI

The classic opioid toxidrome comprises central nervous system depression, miosis, and severe hypoventilation (decreased respiratory rate and tidal volume); atypical presentations include mydriasis with meperidine and seizures with tramadol.

Naloxone is a competitive mu-opioid receptor antagonist with an elimination half-life of 30 to 90 minutes; because most opioids have far longer durations of action, patients are at high risk for renarcotization after initial resuscitation.

Naloxone titration should prioritize restoring adequate spontaneous ventilation (respiratory rate 10–12 breaths/min) rather than full consciousness, using initial doses of 0.04 to 0.1 mg IV in opioid-dependent patients to avoid precipitated withdrawal; continuous infusions are initiated at two-thirds of the effective waking bolus per hour.

Alcohol withdrawal reflects chronic GABA-A downregulation and NMDA upregulation; symptom-triggered benzodiazepine therapy (CIWA-Ar) reduces treatment duration and cumulative doses, with diazepam providing an auto-taper in non-cirrhotic patients and lorazepam preferred in hepatic failure.

Phenobarbital (10–15 mg/kg IV loading dose) increases GABA-A channel open duration, directly opens chloride channels at higher doses, and inhibits AMPA glutamate receptors, reducing ICU admissions and intubations in benzodiazepine-resistant withdrawal; dexmedetomidine does not prevent seizures or DTs.

Last updated: October 2026

8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes

Note

Independent BCEMP study resource provided by ExamFinch. Content is organized around clinical toxicology and emergency medicine pharmacotherapy principles.

Opioid Toxidrome & Receptor Pharmacology

Opioid receptor agonists remain central to acute analgesic therapy but represent a leading cause of fatal poisoning. Opioids exert their pharmacodynamic actions via G-protein-coupled receptors: mu ( μ \mu μ ) , kappa ( κ \kappa κ ) , and delta ( δ \delta δ ) . OPIOID RECEPTOR PHARMACOLOGY

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ Receptor Type │ Primary Physiological & Toxicological Effects │
  • ├───────────────┼─────────────────────────────────────────────────────────────┤
  • │ Mu (μ) │ Supraspinal/spinal analgesia, respiratory depression, │
  • │ │ euphoria, miosis, sedation, decreased gastrointestinal │
  • │ │ motility, physical dependence, bradycardia. │
  • ├───────────────┼─────────────────────────────────────────────────────────────┤
  • │ Kappa (κ) │ Spinal analgesia, miosis, dysphoria, hallucinations, │
  • │ │ sedation, diuresis. │
  • ├───────────────┼─────────────────────────────────────────────────────────────┤
  • │ Delta (δ) │ Spinal/supraspinal analgesia, modulation of μ-receptor │
  • │ │ tolerance, pro-convulsant activity at high doses. │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Cellular Mechanism of Respiratory Depression

Mu-opioid receptors are densely concentrated within the brainstem respiratory rhythm generators, specifically the pre-Bötzinger complex in the ventrolateral medulla. Agonist binding inhibits adenylyl cyclase, activates inward-rectifying potassium channels, and inhibits voltage-sensitive calcium channels. This blunts the central respiratory drive and decreases medullary sensitivity to hypercapnia and hypoxemia. The resulting hypoventilation is characterized by both a reduced respiratory rate and decreased tidal volume .

The Classic Toxidrome & Atypical Presentations

Classic Toxidrome Triad : Central nervous system depression (stupor or coma), miosis (pinpoint pupils), and severe hypoventilation ( < 10 – 12 breaths/min <10–12\text{ breaths/min} < 10–12 breaths/min ).

Associated Findings : Hypothermia, bradycardia, hypotension, hyporeflexia, and diminished or absent bowel sounds (paralytic ileus).

Atypical Features & Toxicological Pitfalls :

Mydriasis (Dilated Pupils) : Meperidine (due to anticholinergic activity of its metabolite normeperidine), propoxyphene, diphenoxylate-atropine, tramadol, or severe anoxic brain injury.

Seizures : Meperidine (accumulation of normeperidine , which lowers the seizure threshold, particularly in renal dysfunction), tramadol (inhibits serotonin and norepinephrine reuptake and antagonizes GABA), and propoxyphene.

QTc Prolongation & Dysrhythmias : Methadone (potent blocker of hERG voltage-gated potassium channels, predisposing to Torsades de Pointes) and massive overdoses of loperamide (blocks cardiac sodium and potassium channels, triggering polymorphic VT and cardiac arrest).

Non-Cardiogenic Pulmonary Edema : Acute heroin, methadone, or fentanyl overdose can precipitate rapid post-resuscitation non-cardiogenic pulmonary edema secondary to precapillary hypoxemic injury and negative-pressure barotrauma from inspiring against a closed glottis.

Naloxone Pharmacology & Continuous Infusion Protocols

Naloxone is a pure, competitive antagonist at mu, kappa, and delta opioid receptors, with highest affinity for the mu receptor. It rapidly displaces opioid agonists from receptor binding sites, reversing coma and respiratory depression.

Pharmacokinetics & The 'Renarcotization' Trap

Onset of Action : 1 to 2 minutes intravenously; 2 to 5 minutes intramuscularly, subcutaneously, or intranasally.

Elimination Half-Life : 30 to 90 minutes (effective clinical duration: 45 to 90 minutes).

The Renarcotization Trap : The elimination half-life of naloxone is substantially shorter than that of virtually all ingested or administered opioids:

  • Morphine half-life: 2 to 4 hours
  • Oxycodone half-life: 3 to 5 hours
  • Methadone half-life: 24 to 36 hours
  • Sustained-release formulations: 12 to 24 hours
  • Synthetic lipophilic fentanyl analogues: prolonged redistribution from adipose tissue depots

When naloxone clears from receptor sites while high circulating agonist concentrations persist, the patient lapses back into life-threatening respiratory arrest ( renarcotization ).

Titration Philosophy & Dosing Algorithm

Important

The clinical objective of naloxone therapy is adequate spontaneous ventilation (respiratory rate 10 to 12 breaths/min, adequate tidal volume, S p O 2 > 90 % SpO_2 > 90\% Sp O 2 ​ > 90% )—NOT full alertness or immediate consciousness.

Precipitating acute opioid withdrawal in an opioid-dependent patient induces an uncontrolled sympathetic surge, profound agitation, tachycardia, hypertension, and projectile vomiting with catastrophic pulmonary aspiration risk. NALOXONE TITRATION ALGORITHM

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ 1. APNEIC / IMPENDING ARREST / UNKNOWN HISTORY: │
  • │ • Administer Naloxone 0.4–2 mg IV, IM, or IN immediately. │
  • │ • Support ventilation with Bag-Valve-Mask and 100% O2. │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 2. OPIOID-DEPENDENT PATIENT WITH SPONTANEOUS VENTILATION (RR < 8–10): │
  • │ • Start with LOW DOSE: 0.04 to 0.1 mg IV. │
  • │ • Titrate upward every 2–3 minutes: 0.04 mg ──> 0.1 mg ──> 0.4 mg ──> 2mg│
  • │ • STOP when spontaneous respiratory rate reaches 10–12 breaths/min. │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 3. RECURRENT HYPOVENTILATION (LONGER-ACTING AGENTS): │
  • │ • Initiate Continuous Naloxone Infusion using the Two-Thirds Rule. │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Continuous Naloxone Infusion Protocol (The Two-Thirds Rule)

When a patient experiences recurrent respiratory depression following bolus reversal (especially with methadone or extended-release opioids), a continuous infusion is indicated:

Calculate the Infusion Rate : Administer two-thirds (2/3) of the initial successful 'waking/reversal bolus' dose per hour as a continuous intravenous infusion. Hourly Infusion Rate = 2 3 × Effective Waking Bolus Dose \text{Hourly Infusion Rate} = \frac{2}{3} \times \text{Effective Waking Bolus Dose} Hourly Infusion Rate = 3 2 ​ × Effective Waking Bolus Dose Worked Example : If a patient with methadone overdose required a cumulative dose of 0.6 mg IV to achieve adequate spontaneous ventilation, the initial continuous infusion rate is: Infusion Rate = 2 3 × 0.6 mg = 0.4 mg/hour \text{Infusion Rate} = \frac{2}{3} \times 0.6\text{ mg} = 0.4\text{ mg/hour} Infusion Rate = 3 2 ​ × 0.6 mg = 0.4 mg/hour

Infusion Preparation : Dilute 4 mg of naloxone in 1,000 mL D5W or 0.9% NaCl (concentration: 4 mcg/mL) and titrate via smart infusion pump.

Breakthrough Hypoventilation : If the patient develops recurrent hypoventilation during the infusion, administer half of the original waking bolus (0.3 mg IV) and increase the infusion rate by 50%.

Alcohol Withdrawal Syndrome: Neurobiology & CIWA-Ar

Alcohol (ethanol) withdrawal syndrome (AWS) is a hyper-excitable neurochemical state resulting from the abrupt cessation of chronic alcohol exposure. NEUROBIOLOGY OF ALCOHOL WITHDRAWAL

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ CHRONIC ETHANOL EXPOSURE: │
  • │ • Allosteric down-regulation & conformational uncoupling of inhibitory │
  • │ GABA-A receptors (decreased chloride conductance) │
  • │ • Compensatory up-regulation of excitatory NMDA (glutamate) receptors │
  • │ and voltage-gated calcium channels │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ ABRUPT WITHDRAWAL: │
  • │ • Sudden loss of GABAergic inhibitory tone │
  • │ • Unchecked, massive NMDA-mediated glutamatergic excitotoxicity │
  • │ • Profound central and autonomic sympathetic hyperactivity (NE/Epi surge) │
  • │ • Manifests as tremor, agitation, seizures, hyperthermia, and delirium │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Timeline of Withdrawal Manifestations

Stage Time Post-Cessation Clinical Features Pathophysiology

Minor Withdrawal 6 to 12 hours Generalized tremor, anxiety, diaphoresis, headache, insomnia, mild tachycardia, hypertension, and GI upset. Autonomic rebound from sympathetic disinhibition.

Alcoholic Hallucinosis 12 to 24 hours Visual, auditory, or tactile perceptions occurring in an otherwise clear sensorium (patient is fully oriented). Altered sensory gating; distinct from delirium.

Withdrawal Seizures 24 to 48 hours Generalized tonic-clonic convulsions; single or short burst ('flurry'); usually non-epileptic in origin. Cortical hyperexcitability from massive NMDA disinhibition.

Delirium Tremens (DTs) 48 to 96 hours Severe fluctuating delirium , profound disorientation, violent agitation, hallucinations, and extreme autonomic instability (severe hyperthermia, drenching sweats, marked tachycardia, hypertension). Untreated mortality is 5% to 15%; requires intensive ICU sedation.

CIWA-Ar Protocol & Symptom-Triggered Therapy

The Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) is a validated 10-item instrument:

Score Stratification : < 8 <8 < 8 points (mild withdrawal; supportive care); 8 to 15 points (moderate withdrawal; pharmacotherapy indicated); > 15 >15 > 15 points (severe withdrawal; aggressive pharmacotherapy, consider ICU admission).

Symptom-Triggered vs. Fixed-Schedule Regimens : Multiple randomized controlled trials demonstrate that symptom-triggered benzodiazepine administration guided by CIWA-Ar significantly reduces total medication doses, shortens treatment duration, and prevents oversedation compared to fixed-schedule tapering.

Limitations : CIWA-Ar requires an awake, cooperative, and communicative patient. It is invalid in delirious, intubated, or encephalopathic patients , where objective sedation scales (such as the Richmond Agitation-Sedation Scale [RASS]) must guide therapy.

Benzodiazepines vs. Phenobarbital Regimens

Sedative-hypnotics that enhance GABAergic neurotransmission represent the cornerstone of alcohol withdrawal pharmacotherapy.

Benzodiazepines: Diazepam vs. Lorazepam

Benzodiazepines are positive allosteric modulators of GABA-A receptors, increasing the frequency of chloride channel opening in the presence of endogenous GABA.

Parameter Diazepam Lorazepam

Lipophilicity & Onset High lipophilicity; rapid brain penetration; onset 1 to 3 minutes IV . Intermediate lipophilicity; slower onset of action ( 5 to 15 minutes IV ).

Metabolism Phase I hepatic oxidation via CYP2C19/3A4 to long-acting active metabolites ( desmethyldiazepam/nordiazepam , t 1 / 2 ≈ 30 – 100 h t_{1/2} \approx 30–100\text{ h} t 1/2 ​ ≈ 30–100 h ). Phase II hepatic glucuronidation directly to inactive glucuronides; no active metabolites .

Elimination Half-Life Parent: 20–50 hours; Active metabolite: up to 100 hours . 10 to 20 hours .

Clinical Advantage Active metabolites provide an inherent, smooth 'auto-taper' , preventing rebound withdrawal and breakthrough seizures. Preferred in advanced liver disease, cirrhosis, and the elderly , because glucuronidation pathways remain preserved.

Dosing Regimen 10 to 20 mg IV every 10 to 15 minutes until patient is calm and lightly sedated (RASS -1 to 0). 2 to 4 mg IV every 15 to 20 minutes until patient is calm and lightly sedated (RASS -1 to 0).

Phenobarbital Loading Protocol

Phenobarbital is a long-acting barbiturate with distinct pharmacological advantages over benzodiazepines in severe withdrawal:

Distinct GABA-A Mechanism : Phenobarbital binds to the barbiturate site on GABA-A receptors to increase the duration of chloride channel opening (rather than frequency).

GABA-Independent Activity : At higher concentrations, phenobarbital directly opens chloride channels even in the absence of endogenous GABA —overcoming the benzodiazepine resistance that occurs when endogenous GABA stores are depleted.

AMPA Glutamate Antagonism : Phenobarbital directly blocks excitatory AMPA and kainate glutamate receptors , suppressing the neurotoxic glutamatergic surge of withdrawal.

Pharmacokinetics : Elimination half-life of 80 to 120 hours provides an ultra-smooth intrinsic multi-day auto-taper, eliminating rebound withdrawal.

Emergency Department Protocol : Weight-based loading dose of 10 to 15 mg/kg IV cumulative (administered either as a 10 mg/kg IV infusion over 30 minutes, or divided doses of 130 to 260 mg IV every 15 to 30 minutes) titrated to light sedation (RASS -1 to 0). Clinical trials confirm phenobarbital reduces ICU admission rates and endotracheal intubations in severe AWS.

Adjunctive Sympatholytics & Critical Safety Pitfalls

Dexmedetomidine is a centrally acting selective alpha-2 adrenergic agonist that inhibits norepinephrine release from the locus coeruleus, reducing autonomic storm (tachycardia, hypertension, diaphoresis) and treating agitation.

Caution

Dexmedetomidine must NEVER be used as monotherapy for alcohol withdrawal.

Dexmedetomidine has zero activity at GABA-A receptors and does not block NMDA receptors . While it normalizes blood pressure and heart rate, it provides no protection against withdrawal seizures or Delirium Tremens . Utilizing dexmedetomidine as monotherapy masks vital signs of escalating neurochemical withdrawal, allowing underlying excitotoxicity to progress silently to status epilepticus or fulminant DTs. It must strictly serve as an adjunct to GABA-active therapy.